QTRX

BEARISH

$3.5 Live

Quanterix Corporation · NASDAQ

Target $6.67 (+90.5%)

$3.23 52W Range $8.77

QTRX Quanterix Corporation - Fundamental Analysis

BEARISH

Console Chart News

QTRX Stock | Fundamental Analysis & Investment Insights

NASDAQ • Healthcare • Medical Devices

Current Price Live

$3.5

Analyst Target

$6.67

+90.5% Upside

52W High

$8.77

52W Low

$3.23

Overview AI Snowflake Price Valuation Profitability Growth Health Statements Peers Insiders SEC Filings

At a glance

Key valuation, profitability, growth, and risk metrics.

Updated Apr 18, 2026

Market cap

$164.29M

P/E

N/A

ROE

-34.2%

Profit margin

-77.1%

Debt/Equity

0.13

Dividend yield

N/A

AI Analysis

AI-powered fundamental assessment

Confidence

85%

QTRX exhibits severe financial distress as evidenced by a Piotroski F-Score of 1/9, indicating critical weakness in operational efficiency and financial health. While the company maintains strong top-line revenue growth (24.7% YoY) and a healthy current ratio (2.84), these are overshadowed by a devastating profit margin of -77.14% and a consistent track record of missing earnings estimates. The stock is in a clear long-term downtrend, having lost over 94% of its value over five years, and currently trades at a significant discount to book value (P/B 0.55), suggesting a 'value trap' scenario.

Key Strengths

Strong YoY revenue growth of 24.70%

Low leverage with a Debt/Equity ratio of 0.13

Strong short-term liquidity (Current Ratio 2.84)

Positive Gross Margin of 46.77%

Trading below book value (P/B 0.55)

Key Risks

Critical operational health (Piotroski F-Score 1/9)

Deeply negative profitability (Profit Margin -77.14%)

Poor earnings reliability (Average surprise -41.54% over last 4 quarters)

Severe long-term price depreciation (5Y Change -94.1%)

Bearish technical trend (0/100)

AI Fair Value Estimate

Based on comprehensive analysis

$4.1

+17.1% above current price

Performance Snowflake

Multi-dimensional analysis across 5 key categories

Overall

Weak

Value

Future

Past

Health

Dividend

AI Verdict

High Risk / Speculative

Key drivers: Extreme operational inefficiency, Revenue growth failing to scale into profit, Persistent bearish price action

Confidence

90%

Value

40/100

Trades at a discount to assets, but assets are not generating returns.

Positives

Low Price/Sales (1.18)
Price/Book below 1.0

Watchpoints

No P/E ratio due to losses
No Graham Number available

Future

45/100

Growth is present in sales but deteriorating in earnings quality.

Positives

Consistent double-digit revenue growth

Watchpoints

Negative YoY EPS growth (-56.7%)
Frequent earnings misses

Past

10/100

Long-term historical performance is extremely poor.

Positives

No standout positives identified.

Watchpoints

Catastrophic 5-year return (-94.1%)
Consistent downward price trajectory

Health

15/100

Balance sheet liquidity is the only saving grace against operational failure.

Positives

Low Debt/Equity
High Current Ratio

Watchpoints

Piotroski F-Score of 1/9

Dividend

0/100

Non-dividend paying growth company.

Positives

No standout positives identified.

Watchpoints

No dividend payments

Stock Price & Analyst Targets

Real-time price movements and analyst price targets

Current Price

$3.5

Analyst Target

$6.67

Upside/Downside

+90.5%

Multi-Horizon Performance vs Peers

Price momentum across 5Y → 1W horizons for QTRX and closest competitors.

Updated 2026-04-17

Company	5Y	3Y	1Y	6M	1M	1W
QTRX Quanterix Corporation Primary	-94.1%	-71.3%	-32.0%	-40.3%	-22.6%	+4.2%
DERM Journey Medical Corporation Peer	-50.0%	+251.1%	-28.9%	-34.4%	-38.3%	+5.5%
ACH Accendra Health, Inc. Peer	-92.8%	-89.2%	-85.8%	-73.2%	-22.1%	-16.3%
QIPT Quipt Home Medical Corp Peer	-44.7%	-42.7%	+56.0%	+34.2%	+1.1%	0.0%
LFMD LifeMD, Inc. Peer	-74.2%	+107.8%	-30.3%	-43.8%	-14.5%	-1.1%

QTR

Quanterix Corporation

Primary

-94.1%

-71.3%

-32.0%

-40.3%

-22.6%

+4.2%

DER

Journey Medical Corporation

Peer

-50.0%

+251.1%

-28.9%

-34.4%

-38.3%

+5.5%

ACH

Accendra Health, Inc.

Peer

-92.8%

-89.2%

-85.8%

-73.2%

-22.1%

-16.3%

QIP

Quipt Home Medical Corp

Peer

-44.7%

-42.7%

+56.0%

+34.2%

+1.1%

0.0%

LFM

LifeMD, Inc.

Peer

-74.2%

+107.8%

-30.3%

-43.8%

-14.5%

-1.1%

Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.

Historical Performance Trends

Long-term financial metrics and growth patterns

Revenue & Net Income

Profit & Operating Margins

Return on Equity (ROE)

Quarterly Revenue Growth

Historical data shows last 12 quarters (3 years)

Valuation Metrics

Key valuation ratios and pricing indicators

N/A

-1.83

N/A

0.55

1.18

0.6

-1.16

$164.29M

Profitability

Profit margins and return metrics

Profit Margin -77.14%

Operating Margin -48.2%

Gross Margin 46.77%

ROE -34.25%

ROA -13.11%

Growth

Revenue and earnings growth rates

Revenue Growth +24.7%

Earnings Growth N/A

Q/Q Revenue Growth +28.36%

Q/Q Earnings Growth N/A

Financial Health

Balance sheet strength and liquidity metrics

Debt/Equity

0.13

Low debt

Current Ratio

2.84

Strong

Quick Ratio

1.98

Excellent

Cash/Share

$2.52

Financial Statement Flow

Interactive flow visualization showing how money moves through the company Q4 2025

Revenue

$0.0B

Gross Margin

45.6%

Op. Margin

-54.5%

Net Margin

-52.8%

Total Assets

$0.4B

Liabilities

$0.1B

Equity

$0.3B

Debt/Equity

0.42x

Operating CF

$-0.0B

Free Cash Flow

$-0.0B

FCF Yield

99%

Quarterly Earnings History

EPS performance vs analyst estimates

2026-05-07

$N/A

2026-03-02

$-0.47

+2.1% surprise

2025-11-10

$-0.73

-37.7% surprise

2025-08-07

$-0.77

-89.0% surprise

Healthcare Sector Comparison

Comparing QTRX against 421 companies in the Healthcare sector (25 bullish, 134 neutral, 262 bearish)

Return on Equity (ROE)

-34.25%

This Stock

-100.15%

Sector Avg

-65.8% (Below Avg)

Profit Margin

-77.14%

This Stock

-13.63%

Sector Avg

+466.0% (Superior)

Debt to Equity

0.13

This Stock

3.22

Sector Avg

-96.1% (Less Debt)

Revenue Growth

24.7%

This Stock

121.05%

Sector Avg

-79.6% (Slower)

Current Ratio

2.84

This Stock

4.55

Sector Avg

-37.6% (Weaker)

Similar Companies

Peer comparison within the same industry

Company	AI Rating	Market Cap	P/E	ROE	Profit Margin	Price
QTRX Quanterix Corporation	BEARISH	$164.29M	-	-34.2%	-77.1%	$3.5
DERM Journey Medical Corporation	BEARISH	$164.62M	-	-44.0%	-18.5%	$4.95	Compare
ACH Accendra Health, Inc.	BEARISH	$163.2M	-	-196.4%	-12.4%	$2.11	Compare
QIPT Quipt Home Medical Corp	BEARISH	$162.3M	-	-9.3%	-4.0%	$3.65	Compare
LFMD LifeMD, Inc.	BEARISH	$166.47M	-	-131.2%	7.4%	$3.47	Compare

QTRX Quanterix Corporation

BEARISH

Mkt Cap

$164M

P/E

ROE

-34.2%

Price

$3.5

Compare with QTRX

ACH Accendra Health, Inc.

Compare with QTRX

QIPT Quipt Home Medical Corp

Compare with QTRX

Compare with QTRX

Recent Insider Trading

Insider buy and sell transactions from the last 6 months

Date	Insider	Position	Transaction	Shares	Value
2026-04-01	DONNELLY WILLIAM P	Officer and Director	Stock Award	6,178	-
2026-04-01	MENDEL SCOTT	Director	Stock Award	4,310	-
2026-03-31	MILLER MICHAEL FRANCIS	Chief Operating Officer	Stock Award	229	-
2026-03-13	SRIRAM VANDANA	Chief Financial Officer	Stock Award	1,833	-
2026-03-13	MILLER MICHAEL FRANCIS	Chief Operating Officer	Stock Award	1,558	-
2026-02-13	SRIRAM VANDANA	Chief Financial Officer	Stock Award	777	-
2026-01-02	DONNELLY WILLIAM P	Officer and Director	Stock Award	2,377	-
2026-01-02	LAI-GOLDMAN MYLA P	Director	Stock Award	25,316	-
2026-01-02	FLYNN KAREN A	Director	Stock Award	23,372	-
2026-01-02	ELLIOTT JEFFREY THOMAS	Director	Stock Award	23,372	-
2026-01-02	HAMPTON MALCOLM GARRET	Director	Stock Award	23,372	-
2026-01-02	MEISTER PAUL M	Director	Stock Award	3,974	-
2026-01-02	WALT DAVID R	Director	Stock Award	1,215	-
2026-01-02	MENDEL SCOTT	Director	Stock Award	25,316	-
2026-01-02	MAGOVCEVIC-LIEBISCH IVANA	Director	Stock Award	23,372	-

DONNELLY WILLIAM P

Officer and Director

Stock Award

2026-04-01

6,178 shares

MENDEL SCOTT

Director

Stock Award

2026-04-01

4,310 shares

MILLER MICHAEL FRANCIS

Chief Operating Officer

Stock Award

2026-03-31

229 shares

SRIRAM VANDANA

Chief Financial Officer

Stock Award

2026-03-13

1,833 shares

MILLER MICHAEL FRANCIS

Chief Operating Officer

Stock Award

2026-03-13

1,558 shares

SRIRAM VANDANA

Chief Financial Officer

Stock Award

2026-02-13

777 shares

DONNELLY WILLIAM P

Officer and Director

Stock Award

2026-01-02

2,377 shares

LAI-GOLDMAN MYLA P

Director

Stock Award

2026-01-02

25,316 shares

FLYNN KAREN A

Director

Stock Award

2026-01-02

23,372 shares

ELLIOTT JEFFREY THOMAS

Director

Stock Award

2026-01-02

23,372 shares

HAMPTON MALCOLM GARRET

Director

Stock Award

2026-01-02

23,372 shares

MEISTER PAUL M

Director

Stock Award

2026-01-02

3,974 shares

WALT DAVID R

Director

Stock Award

2026-01-02

1,215 shares

MENDEL SCOTT

Director

Stock Award

2026-01-02

25,316 shares

MAGOVCEVIC-LIEBISCH IVANA

Director

Stock Award

2026-01-02

23,372 shares

Insider transactions can signal confidence or concerns about company prospects

SEC Filings

Recent regulatory filings from the SEC EDGAR database

8-K

2026-03-02

QTRX filed an 8-K on March 2, 2026, likely to announce its annual financial results for the preceding fiscal year.

10-K

2026-03-02

QTRX filed its 10-K annual report on March 2, 2026, which includes sections on business operations, risk factors, and management's discussion and analysis. Specific financial highlights and risk details were not provided in the available excerpts.

8-K

2026-01-08

8-K

2025-11-20

10-Q

2025-11-10

QTRX has expanded through the acquisitions of Emission and Akoya, incurring potential earnout payments of up to $60 million and ongoing royalty obligations of $1-2 million annually through 2033. The company faces continued financial risks including uncapped royalty payments and ongoing development costs for a diagnostic test, which have historically ranged from $10 million to $11 million.

8-K

2025-11-10

QTRX filed an 8-K on November 10, 2025, likely to announce its third-quarter financial results.

8-K

2025-10-02

QTRX filed an 8-K on October 2, 2025, likely to announce its third-quarter financial results.

8-K

FORM 8-K

2025-09-24

8-K/A

2025-09-23

QTRX filed an amendment to a previously submitted current report (Form 8-K) on September 23, 2025.

DEF 14A

2025-08-25

QTRX filed a definitive proxy statement on August 25, 2025, providing shareholders with information regarding matters to be voted on at an upcoming meeting.

10-Q

2025-08-07

8-K

2025-08-07

8-K

2025-08-04

8-K

2025-07-24

8-K

2025-07-18

Data sourced from SEC EDGAR. AI summaries generated automatically.

Wall Street Analysts

Professional analyst ratings and price targets

Consensus

HOLD

3 analysts

Canaccord Genuity

2025-12-22

Maintains

Hold Hold

Past News Coverage

Recent headlines mentioning QTRX from our newsroom.

Newest → oldest

Back to All Stocks

TradingGPT V2 Copilot

Fundamentals • Valuation • Risk

Hi! I'm your fundamentals copilot.

Ask me to:
• Summarize the business quality
• Review valuation and multiples
• Highlight risks and red flags
• Explain growth and margin trends

QTRX

QTRX Quanterix Corporation - Fundamental Analysis

At a glance

AI Analysis

Key Strengths

Key Risks

Performance Snowflake

Stock Price & Analyst Targets

Multi-Horizon Performance vs Peers

Historical Performance Trends

Revenue & Net Income

Profit & Operating Margins

Return on Equity (ROE)

Quarterly Revenue Growth

Valuation Metrics

Profitability

Growth

Financial Health

Financial Statement Flow

Quarterly Earnings History

Healthcare Sector Comparison

Similar Companies

Recent Insider Trading

SEC Filings

Wall Street Analysts

Past News Coverage

Wait — Don't Miss Out!